PROGRAMME

MARCH 16

09:00 SESSION 1:
New discoveries on the mechanism of inhibitor development

Chairs: Pier Mannuccio Mannucci (Italy), Donna Di Michele (USA)
Roadmap for improved haemophilia treatment
Flora Peyvandi (Italy)
Speed bumps on the innovation highway
Donna Di Michele (USA)
Unexpected guests; Stabilin‐2 as a regulatory factor for inhibitor development
David Lillicrap (Canada)
IDO1 and inhibitor development in hemophilia A
Davide Matino (Italy)
10:40 Coffee break & Poster Session
11:00 SESSION 1 (continued)
Chairs: Jan Voorberg (The Netherlands), Christoph Königs (Germany)
Quantification and phenotyping of factor VIII-specific T cells in healthy donors
Bernard Maillère (France)
Antigen presentation in inhibitor development: new discoveries
Sébastien Lacroix-Desmazes (France)
To serve and protect: modulating effect of von Willebrand factor on FVIII peptide presentation
Jan Voorberg (The Netherlands)
12:30 ORAL COMMUNICATION SESSION
Industry research

Chairs: David Lillicrap (Canada), Elena Santagostino (Italy)
Emicizumab prophylaxis in adolescent/adult patients with haemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 Study.
Maria Elisa Mancuso (Italy)
Role of rFVIIIFc in immune tolerance induction in severe hemophilia A patients with Inhibitors
Nisha Jain (USA)
Efficacy, safety, and pharmacokinetics of once-weekly emicizumab prophylaxis in paediatric persons with haemophilia A (PwHA) with inhibitors two years old or younger in the HAVEN 2 Study
Flora Peyvandi (Italy)
Low immunogenicity of human-cell-derived recombinant FVIII in previously untreated patients with non-null F8 mutations
Anna Pavlova (Germany)
Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia
Torben Colberg (USA)
Real-World safety and benefit of early treatment with room temperature-stable recombinant activated Factor VII (rFVIIa) in patients with haemophilia A or B with inhibitors: SMART-7™ study results
Kaan Kavakli (Turkey), on behalf of the SMART-7™ steering committee
13:30 Lunch
14:30 SESSION 2:
New developments for tolerance induction

Chairs: Flora Peyvandi (Italy), Federico Mingozzi (France)
Gene therapy and new approaches for tolerance induction Federico Mingozzi (France)
Federico Mingozzi (France)
Liver induced tolerance
Percy Knolle (Germany)
15:30 Coffee break & Poster Session
16:00 SESSION 2 (continued)
Chairs: Luigi Naldini (Italy), David Lillicrap (Canada)
Engineering regulatory T cells: Driving CARs to BARs
David Scott (USA)
Perspectives of Immune Tolerance Induction (ITI) in the era of new haemophilia treatment options
Johannes Oldenburg (Germany)
Alternatives to human VIII – orthologs, ancestors and hybrids thereof
Christopher B. Doering (USA)
17:30 WALKING ORAL COMMUNICATIONS SESSION
Foyer in front of the Plenary Hall (with refreshments)

Chairs: Donna Di Michele (USA), Frits Rosendaal (The Netherlands)
Generation and characterization of humanized hemophilic mice expressing HLA-DRB1*0101
Jules Russick (France)
Recombinant FVIII product type and the risk of inhibitor development in previously treated patients with hemophilia A: a systematic review and meta-analysis
Shermarke Hassan (The Netherlands)
SIPPET effect on Turkisk previously untreated patients (PUP) with severe hemophilia A: National data
Kaan Kavakli (Turkey)
Identification and functional characterization of a novel consensus sequence splicing mutation of factor VIII (FVIII) coagulation gene associated with severe hemophilia A and inhibitors development
Rosella Famà (Italy)
Single center experience in the treatment of haemophilia A PUPs
Susan Halimeh (Germany)
Lot-matching decreases the time for Immune Tolerance Induction (ITI): Preliminary results of the ObsITI study
Jonathan Ducore (USA)
Severe acquired von Willebrand syndrome (type 3-like): a case report
Francesca Stufano (Italy)
Discussion and question and answers
19:00 End of sessions

MARCH 17

09:00 Lecture: Evolving inhibitor incidence over time
Frits R. Rosendaal (The Netherlands)
09:30 SESSION 3:
Treatment of inhibitors in hemophilia

Chairs: Sébastien Lacroix-Desmazes (France) and Michael Makris (UK)
Development of SerpinPC as a pan-haemophilia agent
Jim Huntington (UK)
Standard and novel approaches for treatment and prevention of bleeding episodes in patients with inhibitors
Roseline D’OIRON (France)
CAR/BAR mediated treatment of haemophilia A
Christoph Konigs (Germany)
11:00 Coffee break
11:30 SESSION 3 (continued)
Chairs: Sébastien Lacroix-Desmazes (France) and Michael Makris (UK)
How to measure the efficacy of treatment in patients with inhibitors (Laboratory assays)
Steven Kitchen (UK)
How to manage surgery in inhibitors patients with standard and novel therapies
Maria Elisa Mancuso (Italy)
Conclusive remarks
Flora Peyvandi (Italy)
13:00 End of sessions